SGLT2 Inhibitors

Sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors) are a class of oral antidiabetic medications that has profoundly changed the treatment of type 2 diabetes mellitus because, although developed as glucose-lowering agents, they have demonstrated clinically relevant effects on the heart, kidneys, blood pressure, body weight and hemodynamic load. Their target is the renal proximal tubule, where they block the main system responsible for reabsorbing filtered glucose. This action induces glycosuria and natriuresis, but the pathophysiological scope of the class extends far beyond urinary glucose excretion: downstream effects involve glomerular hemodynamics, extracellular volume, energy metabolism, uric acid levels and cardiorenal stress. Gliflozins can therefore no longer be regarded merely as medications “to lower blood glucose,” but as therapeutic agents with a distinct cardiorenal-metabolic identity.

In contemporary clinical practice, the class mainly includes empagliflozin, dapagliflozin, canagliflozin and ertugliflozin, with differences among individual agents in pharmacological selectivity, pivotal trials, approved indications and the breadth of cardiovascular and renal outcome evidence. Their glucose-lowering effect is insulin-independent, a feature that makes these medications useful even when beta-cell function is already reduced. Their efficacy for glycemic control tends to diminish as glomerular filtration rate falls, whereas cardiorenal benefits may persist even with less well-preserved kidney function. Their use is therefore increasingly guided not only by glycated hemoglobin, but by the patient’s overall profile, including the presence of atherosclerotic cardiovascular disease, heart failure, albuminuria, chronic kidney disease, obesity, hypoglycemic risk, advanced age, concomitant diuretic therapy and vulnerability to class-specific adverse events.

The rationale for SGLT2 inhibitors arises from renal glucose physiology. Under normal conditions, the kidneys filter a large amount of glucose each day and reabsorb almost all of it in the proximal tubule. Most reabsorption depends on SGLT2, expressed mainly in the initial segment of the proximal tubule, whereas the remaining fraction is recovered more distally by sodium-glucose cotransporter 1. In type 2 diabetes mellitus, the kidneys do not merely sustain injury from hyperglycemia, but actively help maintain it by increasing the renal glucose threshold and promoting reabsorption of even larger amounts of filtered glucose. This creates a maladaptive circuit in which the kidneys, instead of facilitating elimination of the excess glycemic load, help retain it.

By blocking SGLT2, gliflozins interrupt this circuit. Unreabsorbed glucose is excreted in the urine, and blood glucose falls independently of insulin action and residual beta-cell secretory capacity. This point is crucial because it distinguishes the class from secretagogues and all therapies that depend on adequate beta-cell reserve. A patient with long-standing disease, marked insulin resistance or progressive pancreatic functional exhaustion can still obtain a metabolic benefit without direct insulin stimulation. The result is a low intrinsic risk of hypoglycemia during monotherapy or combination with medications that do not cause hypoglycemia, together with relatively flexible integration into treatment regimens.

The modern rationale for the class, however, has become much broader. Simultaneous inhibition of glucose and sodium reabsorption modifies tubuloglomerular feedback: more sodium reaches the macula densa, the afferent arteriolar vasodilation typical of diabetic hyperfiltration is attenuated, and intraglomerular pressure falls. This mechanism explains why gliflozins can slow progression of kidney damage beyond what would be expected from glucose lowering alone. Cardiovascular effects include reduced preload, a slight reduction in afterload, weight loss, lower blood pressure, improvement in interstitial congestion, reduced wall stress and probable effects on myocardial energy metabolism. The clinical benefits observed in heart-failure and chronic-kidney-disease trials have therefore consolidated a view of the class in which blood glucose is only one of the variables corrected.

A further point of major interest is the dissociation between glycemic efficacy and cardiorenal efficacy. As glomerular filtration rate falls, the capacity to induce glycosuria diminishes because the filtered glucose load is lower. Nevertheless, many hemodynamic, tubular and systemic actions persist. This explains why current prescribing criteria are far more nuanced than in the past: the decision to use an SGLT2 inhibitor is not based solely on glycated hemoglobin, but on the primary treatment objective—glycemic control, kidney protection, prevention or treatment of heart failure, cardiovascular risk reduction, and construction of a therapeutic strategy with a low risk of hypoglycemia and a modest favorable effect on weight.

Pharmacologically, SGLT2 inhibitors belong to the gliflozin family, derivatives that selectively block sodium-glucose cotransporter 2 on the luminal membrane of proximal tubular cells. At the molecular level, the medication prevents sodium and glucose cotransport from the tubular lumen into the cell, reducing recovery of filtered glucose and lowering the renal threshold for glycosuria. The action therefore begins strictly in the kidney, but its systemic effects derive from a cascade of metabolic and hemodynamic changes. Urinary glucose loss produces daily caloric loss that contributes to weight reduction, predominantly through fat-mass loss, whereas initial natriuresis and osmotic diuresis help lower blood pressure and extracellular volume.

The individual agents are not perfectly interchangeable. Empagliflozin and dapagliflozin currently have the broadest use profiles in terms of the volume of cardiorenal evidence and the range of clinical indications developed over time. Canagliflozin has provided highly relevant renal and cardiovascular evidence, but historically attracted the greatest attention for certain safety signals, particularly the amputation signal observed in some clinical programs. Ertugliflozin retains a role as a glucose-lowering agent in the class but has a less extensive outcomes evidence base. Other molecules have partly different profiles, such as sotagliflozin, which also inhibits SGLT1, but it is not a pure SGLT2 inhibitor and should be considered separately.

Differences among gliflozins also concern transporter selectivity, pharmacokinetics, authorized indications, pediatric data for some agents and robustness of evidence in different settings. These differences should not, however, be turned into a false concept of absolute heterogeneity. There is clearly a class effect for reducing hospitalization for heart failure and slowing progression of chronic kidney disease, whereas the magnitude of effects on specific atherothrombotic cardiovascular endpoints, the evidence in certain subgroups and formal regulatory indications vary among individual medications. Practical selection should therefore integrate the class concept with the molecule concept: one should ask not only whether the patient is suitable for an SGLT2 inhibitor, but which specific agent has evidence or indications most consistent with the dominant clinical problem.

Several ancillary mechanisms are particularly relevant physiologically. SGLT2 inhibition modifies the activity of other functionally coupled tubular systems, including the sodium-hydrogen exchanger and pathways involved in urate handling, helping reduce serum uric acid. The increase in hematocrit observed in many patients should not be interpreted solely as hemoconcentration from diuresis, but probably also as a sign of altered renal corticomedullary oxygenation and renewed erythropoietin production. Modest reductions in triglycerides, a slight increase in high-density lipoprotein cholesterol and sometimes a small rise in low-density lipoprotein cholesterol are also observed, generally of secondary clinical importance relative to the overall benefit.

Pharmacodynamics also explains the limitations of the class. If blood glucose is very high and the patient is markedly catabolic or insulin-deficient, pharmacologically induced glycosuria alone is insufficient to correct the condition rapidly. Moreover, during metabolic stress, reduced carbohydrate intake, prolonged fasting, surgery, infections or abrupt insulin-dose reduction, the hormonal balance may shift toward greater ketogenesis. This is the setting for the rare but clinically critical possibility of diabetic ketoacidosis, even when blood glucose is not particularly elevated. Correct understanding of the mechanism of action is therefore essential not only to appreciate the advantages of the class, but also to prevent its most serious adverse events.

Treatment with an SGLT2 inhibitor should be based not on the medication itself, but on the dominant clinical profile. In patients with type 2 diabetes mellitus without major comorbidities, these medications are a very valid choice when reductions in glycated hemoglobin and blood pressure, modest but sustained weight loss and a low risk of hypoglycemia are desired. In patients with atherosclerotic cardiovascular disease, heart failure or albuminuric chronic kidney disease, the assessment changes because the medication enters a strategy of organ protection as well as glycemic control. The current decision hierarchy is therefore much more clinical and prognostic than in the past.

Before treatment begins, several essential parameters should be assessed: kidney function, albuminuria, blood pressure, volume status, current diuretic therapy, history of recurrent genital infections, risk of ketosis, dietary pattern, possible alcohol misuse, ulcers or ischemia of the lower limbs, geriatric frailty and likely adherence to temporary-discontinuation rules. In patients with reduced glomerular filtration rate, the glycemic objective must be carefully distinguished from the cardiorenal objective. Glucose-lowering efficacy diminishes at low filtration rates, but the rationale for kidney and cardiovascular protection may remain strong, provided that the selected agent is appropriate and the indication is consistent with the available evidence.

This class integrates well with metformin, glucagon-like peptide 1 receptor agonists, basal insulin and, in many cases, the rest of the antidiabetic armamentarium. Combination with medications that cause hypoglycemia, such as insulin or sulfonylureas, nevertheless requires reassessment of the doses of those agents—not because a gliflozin frequently causes hypoglycemia by itself, but because the overall improvement in glycemic control may reveal preexisting overtreatment. In patients with obesity, combination with an incretin-based agonist is particularly rational because it combines urinary glucose loss, reduced appetite and greater weight-loss efficacy, although cost, complexity and the gastrointestinal profile must be considered.

The practical selection of the ideal candidate can be summarized in the following framework, which must always be interpreted in the actual clinical context.

Clinical profiles in which an SGLT2 inhibitor is particularly rational

• Type 2 diabetes mellitus with heart failure, especially when reducing congestion and hospitalization risk is a priority
• Type 2 diabetes mellitus with chronic kidney disease, particularly with albuminuria or risk of progression
• Type 2 diabetes mellitus requiring glucose reduction while avoiding hypoglycemia and promoting modest weight loss
• Patient with cardiovascular disease or high cardiorenal risk in whom the therapeutic strategy should target prognosis as well as blood glucose

Starting therapy is straightforward from a prescribing standpoint, but should not be superficial from an educational perspective. Patients must understand why they are receiving the medication, what benefit is expected, what is normal during the first few weeks and in which situations treatment should be temporarily stopped. The first perceived effect may be increased urine output, often modest but more noticeable in patients also taking diuretics or with high initial blood glucose. In some cases, the diuretic dose must be reduced, especially if the patient is older, lean, hypotensive or predisposed to dizziness, orthostatic hypotension and worsening kidney function due to volume depletion.

Monitoring of SGLT2 inhibitors should be structured around the mechanisms of the class. Before initiation, it is useful to document serum creatinine, estimated glomerular filtration rate, urinary albumin-to-creatinine ratio when indicated, blood pressure, body weight, glycated hemoglobin and concomitant therapy. In patients with a history of ketosis or unusual dietary patterns, a more detailed assessment of individual metabolic risk may be appropriate. After treatment begins, the clinician should expect several predictable changes: a slight reduction in blood glucose, modest weight loss, a decrease in blood pressure of a few mmHg and sometimes a small initial reduction in estimated glomerular filtration rate. The latter does not automatically indicate nephrotoxicity.

The so-called initial eGFR dip often reflects the hemodynamic effect of restoring tubuloglomerular feedback and reducing intraglomerular hypertension. This concept is important because it prevents inappropriate discontinuation of potentially nephroprotective therapy. The physiological dip must nevertheless be distinguished from true deterioration caused by volume depletion, infection, hypotension, excessive diuretic use, vomiting, diarrhea or intercurrent kidney disease. Monitoring must therefore always integrate laboratory and clinical findings. A patient with a mild decrease in filtration who is stable, normotensive and without signs of hypovolemia often warrants observation and continued therapy; a confused, hypotensive, severely dehydrated patient or one with rapidly rising creatinine requires immediate reassessment.

Follow-up should also assess genitourinary tolerability. Genital fungal infections are the adverse event most characteristically associated with the class. They do not affect most patients, but risk increases in susceptible individuals, those with previous candidiasis, poor local hygiene, markedly uncontrolled diabetes or facilitating anatomical conditions. This adverse effect should neither be dramatized nor trivialized: explaining the initial symptoms, the importance of hygiene and the need for prompt treatment in advance reduces the risk of inappropriate discontinuation.

Metabolic monitoring should also include surveillance for ketoacidosis. Routine ketone testing is not necessary in every patient, but recognizing when to test is essential: nausea, vomiting, abdominal pain, abnormal breathing, marked weakness, reduced caloric intake, acute illness, insulin discontinuation or reduction, alcohol misuse, prolonged fasting and the perioperative period. In these settings, the correct message is not to wait until blood glucose becomes very high, because class-associated ketoacidosis can present with only moderately elevated glucose. Education on situational monitoring is therefore more important than indiscriminate routine testing.

SGLT2 inhibitors have relatively few major pharmacokinetic interactions in everyday practice, but many functional clinical interactions, meaning situations in which their effect is additive to that of other treatments or particular patient conditions. Combination with diuretics is the classic example. Both therapies promote sodium and water loss; consequently, the risk of hypotension and functional worsening of kidney function increases in patients with low blood pressure, geriatric frailty, inadequate fluid intake or heart failure undergoing rapid decongestion. This does not contraindicate the combination, which is often highly useful in heart failure, but it requires dynamic management of doses, weight, symptoms and kidney function.

Combination with insulin and sulfonylureas should be interpreted mainly in terms of hypoglycemia. Gliflozins alone rarely cause hypoglycemia, but they may reduce the dose requirement for medications that lower blood glucose through insulin-dependent mechanisms. A patient who starts therapy with good control or narrow margins should be reassessed early to prevent iatrogenic hypoglycemia that is incorrectly attributed to the new medication. At the same time, insulin-treated patients should not have insulin reduced excessively or abruptly, because a disproportionate reduction can promote ketogenesis and increase the risk of ketoacidosis.

Combination with metformin is rational and well established: the two medications act through different, complementary mechanisms, with a low risk of hypoglycemia and favorable effects on weight and blood pressure. Integration with glucagon-like peptide 1 receptor agonists is also very attractive because it combines independent mechanisms involving the kidneys, appetite, gastric emptying, the incretin axis and energy balance. In patients with type 2 diabetes mellitus and obesity, the combination may be particularly useful when the aim is to act simultaneously on metabolic control, weight and organ protection.

A separate issue is combination with renin-angiotensin system blockers and mineralocorticoid receptor antagonists in patients with kidney or heart disease. Here, the main interest is not glycemic but cardiorenal. These combinations can provide pathophysiologically coherent protection at several levels, but require more precise surveillance of glomerular filtration rate, blood pressure, volume status and, as appropriate, serum potassium. Management should therefore be integrated rather than fragmented by individual specialist or individual medication.

In older patients, an SGLT2 inhibitor can be very useful when the goal is metabolic control with a low risk of hypoglycemia, but assessment must be more nuanced than in a younger adult. Chronological age matters less than frailty profile: low blood pressure, sarcopenia, impaired thirst, diuretic therapy, frequent urinary infections, cognitive decline and reduced ability to follow instructions during acute illness. In a robust, independent older person, the class can provide genuine benefits; in a frail older person prone to dehydration or unable to cooperate, the safety margin narrows and caregiver education becomes an integral part of prescribing.

Gliflozins have acquired a central role in patients with chronic kidney disease. Here it is essential to distinguish their effect on blood glucose from their effect on kidney-disease progression. Even when glucose-lowering capacity becomes more modest because of reduced filtration, the benefit in slowing renal decline and reducing cardiorenal events may retain full clinical relevance. Albuminuria, the eGFR trajectory and risk of progression therefore matter more than glycated hemoglobin alone. In this setting, patients should be clearly told that the medication may be continued not so much because it “still works for sugar,” but because it protects the kidneys and cardiovascular system.

In heart failure, SGLT2 inhibitors have moved beyond their original diabetological identity. Their benefit on hospitalization and worsening-heart-failure endpoints, demonstrated even in populations without diabetes, has made these medications an integral part of modern cardiorenal therapy. When prescribed to a patient with diabetes who is already receiving diuretics, neurohormonal antagonists and sometimes dietary restrictions, however, the clinician must carefully balance the risk of hypovolemia and interpret initial changes in glomerular filtration appropriately.

The situation is different in type 1 diabetes mellitus. Although a metabolic benefit is biologically plausible, the class is associated with an increased risk of diabetic ketoacidosis and is not standard treatment for improving glycemic control. This point must be stated clearly because pathophysiological appeal should not override the safety profile. Similarly, great caution is needed in patients with advanced pancreatic disease, severe insulin deficiency, poor food intake or frequent catabolic states. During the perioperative period, systemic infections, prolonged fasting and severe carbohydrate restriction, the medication often needs to be temporarily discontinued to reduce the risk of ketosis.

Particular attention is required in patients with a history of recurrent genital candidiasis, diabetic-foot disease, severe peripheral ischemia or active ulcers. The class is not automatically prohibited in all these settings, but the risk-benefit balance should be recalculated more cautiously. In a person with a complex diabetic foot or active ischemic lesions, especially if an agent with more debated amputation-related safety signals is being considered, a more conservative approach and very close surveillance are appropriate.

The strategic positioning of SGLT2 inhibitors in modern guidelines derives from outcome trials showing benefits beyond simple glucose reduction. In large cardiovascular studies of patients with type 2 diabetes mellitus, the class consistently reduced hospitalization for heart failure, whereas its effect on major atherothrombotic events varied more among agents and study populations. Subsequent trials specifically addressing heart failure and chronic kidney disease consolidated the role of the class even in patients without diabetes, profoundly changing clinical perceptions of gliflozins.

This has produced a therapeutic strategy with multiple entry points. In a person with type 2 diabetes mellitus and heart failure, the medication is often introduced early because prognostic benefit and reduction in hospitalization risk may take precedence over the glycemic discussion itself. In albuminuric chronic kidney disease, selection is based on the objective of slowing progression to advanced kidney failure and cardiovascular complications. In a person without these comorbidities but requiring an oral agent with a low risk of hypoglycemia and favorable effects on weight and blood pressure, the class still has full utility as part of the antidiabetic strategy.

The renal benefit derives from a combination of factors. In addition to restoration of tubuloglomerular feedback and reduction of hyperfiltration, albuminuria declines, the tubular glucose and sodium load is attenuated, some determinants of inflammation and metabolic stress improve, and the nephron becomes less vulnerable to accelerated progression. On the cardiac side, reduced interstitial volume, modest weight loss, better blood-pressure control, effects on uric acid and vascular stiffness, and possible myocardial metabolic remodeling help explain why the class has had such a consistent impact on heart failure.

Uncritical enthusiasm should nevertheless be avoided. SGLT2 inhibitors do not automatically replace other necessary therapies, compensate for poor nutritional management, eliminate the need for insulin when it is indicated, or dispense with clinical selection. Their strength lies precisely in shifting the strategy from glucose control alone to prognostic protection. The correct clinical question is no longer “how much does it lower glycated hemoglobin?” but “in which patient, with which organ at risk and with which monitoring plan will this medication provide the greatest net benefit?”

The safety profile of SGLT2 inhibitors is generally favorable, but the class has characteristic adverse effects that prescribers must understand precisely. The most common and characteristic event is genital fungal infection, promoted by the higher glucose concentration in urine. These infections are generally mild or moderate and often treatable without sequelae, but they may recur and undermine adherence if the patient has not been adequately informed. Common urinary tract infections do not show a uniform, dramatic increase across all studies, but symptoms, dysuria, fever and clinical deterioration should still be monitored in susceptible individuals.

Volume depletion is another crucial issue. Natriuresis and osmotic diuresis can lead to hypotension, dizziness, weakness, worsening kidney function from hypoperfusion and greater vulnerability in older adults or people taking diuretics. Prevention involves appropriate patient selection, possible adjustment of diuretic therapy, assessment of volume status and clear hydration instructions. This risk should not be confused with direct toxic kidney injury, because the class as a whole has a long-term nephroprotective effect.

The most important serious adverse event is diabetic ketoacidosis, sometimes with blood glucose that is not markedly elevated. Its pathophysiology includes relative reduction in circulating insulin, increased glucagon, greater lipolysis and ketogenesis, especially during fasting, acute illness, surgery, excessive insulin reduction, alcohol misuse or severe carbohydrate restriction. Gliflozins should therefore be stopped before planned surgery and during acute conditions that predispose to ketosis. The practical rule is not merely “stop if the patient is eating little,” but recognize any situation in which metabolism is shifting toward catabolism.

Rare but severe events include Fournier gangrene, a necrotizing fasciitis of the perineum described in association with the class. It is rare but potentially devastating and requires immediate discontinuation, antibiotic therapy and urgent surgical assessment. The amputation signal arose mainly with canagliflozin in some clinical programs and required careful interpretation. The most rational approach today is not to generalize indiscriminately to the entire class, but to remain particularly vigilant in patients with critical limb ischemia, ulcers, deep infections, severe neuropathy or previous amputation.

Other debated issues include fractures, electrolyte abnormalities and risk of acute kidney injury. The evidence does not support a simplistic, uniform interpretation. Fracture risk does not appear to be a classic, consistent effect of the entire category, while the dominant renal finding from trials remains protection, not harm. Clinicians should therefore avoid two opposite errors: trivializing genuinely important events such as ketoacidosis and Fournier gangrene, or attributing widespread, generalized toxicities to the class that are not supported by the overall evidence.

Adherence to SGLT2 inhibitors depends less on dosing complexity, which is usually low, and far more on the quality of therapeutic education. A patient who understands the rationale for the medication, knows that urination may increase somewhat, understands basic hygiene measures, recognizes symptoms that require temporary discontinuation and does not interpret every initial laboratory change as toxicity is more likely to continue treatment and obtain its prognostic benefits. By contrast, lack of counseling often leads to unwarranted discontinuation after initial episodes of candidiasis, increased diuresis or modest fluctuations in creatinine.

Therapy should therefore be accompanied by clear practical instructions. Patients should know that during high fever, vomiting, diarrhea, fasting, surgery, invasive procedures with reduced food intake or major reduction in fluid intake, the medication may need to be temporarily stopped. They should also know that nausea, pronounced malaise, abdominal pain or dyspnea should not be interpreted only as influenza or gastroenteritis, but may require exclusion of ketosis, especially if blood glucose is not dramatically elevated. This is one area in which the quality of information directly changes clinical safety.

Clinicians should also maintain a long-term perspective. Stopping therapy after the first mild, treatable genital infection or because of a modest initial eGFR dip may deprive the patient of meaningful cardiorenal protection. Conversely, persisting despite dehydration, ketosis, complex foot ulcers or recurrent intolerance ignores the principle of individual net benefit. True adherence is not mere persistence of the prescription, but appropriate continuity of a therapy that is understood, monitored and adapted to the clinical course.

Over time, SGLT2 inhibitors have evolved from a simple antidiabetic class into a pillar of cardiorenal-metabolic medicine. Their correct use nevertheless requires specific expertise: knowing how to prescribe them is not enough; clinicians must know how to place them in context. When this is done, the medication is not merely an addition to diabetes treatment, but a tool capable of favorably changing the patient’s clinical trajectory, especially in those whose kidneys and heart are already at risk of progression and recurrent hospitalization.